T-ALL
MCID: PRC049
MIFTS: 48

Precursor T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for Precursor T-Cell Acute Lymphoblastic Leukemia:

Name: Precursor T-Cell Acute Lymphoblastic Leukemia 58
T-All 58 54
Precursor T-Cell Acute Lymphoblastic Leukemia/lymphoma 58
Precursor T-Cell Acute Lymphocytic Leukemia/lymphoma 58
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 71
Precursor T-Cell Acute Lymphocytic Leukemia 58
Adult T-Cell Lymphoma/leukemia 71

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C91.0
UMLS via Orphanet 72 C1961099
Orphanet 58 ORPHA99861
UMLS 71 C0023493 C1961099

Summaries for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards based summary : Precursor T-Cell Acute Lymphoblastic Leukemia, also known as t-all, is related to t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with Precursor T-Cell Acute Lymphoblastic Leukemia is ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Bortezomib and Dasatinib have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and myeloid, and related phenotypes are cellular and embryo

Related Diseases for Precursor T-Cell Acute Lymphoblastic Leukemia

Diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 t-cell acute lymphoblastic leukemia 31.3 TLX3 TLX1 TAL1 STIL NUP214 MYC
2 leukemia, acute lymphoblastic 31.2 TRD TLX1 TAL1 PICALM MYC MYB
3 lymphoblastic lymphoma 31.1 TRB TLX1 TAL1 MYC CDKN2A
4 leukemia, acute lymphoblastic 3 31.1 FLT3 CDKN2A BCR ABL1
5 t-cell lymphoblastic leukemia/lymphoma 31.1 TLX1 TAL1 MYC MYB
6 myeloid leukemia 30.9 PICALM NUP214 MYC FLT3 BCR BAX
7 lymphoma 30.9 TLX1 TAL1 MYC CDKN2A BCL10 BAX
8 acute leukemia 30.8 TAL1 MLLT10 FLT3 BCR
9 leukemia 30.8 TLX3 TLX1 TAL1 PICALM MYC FLT3
10 leukemia, chronic myeloid 30.8 TAL1 MYC MYB FLT3 BCR ABL1
11 childhood leukemia 30.7 CDKN2A BCR ABL1
12 leukemia, acute myeloid 30.7 TAL1 PICALM NUP214 MYC MYB MLLT10
13 myelodysplastic syndrome 30.4 NUP214 MYC MYB FLT3 CDKN2A ABL1
14 burkitt lymphoma 30.3 MYC MYB CDKN2A BCR BAX ABL1
15 b-cell lymphoma 30.2 MYC CDKN2A BCR BCL10 BAX
16 lymphoma, non-hodgkin, familial 29.9 TAL1 MYC MYB FLT3 CDKN2A BCR
17 leukemia, chronic lymphocytic 29.9 MYC MYB FLT3 CDKN2A BCR BCL10
18 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.6 CDKN2A ABL1
19 philadelphia-negative chronic myeloid leukemia 10.6 BCR ABL1
20 primary cutaneous diffuse large b-cell lymphoma, leg type 10.6 MYC CDKN2A
21 cervical adenoid cystic carcinoma 10.6 MYB CDKN2A
22 plasma cell leukemia 10.6 MYC CDKN2A BCL10
23 suppressor of tumorigenicity 3 10.5 MYC CDKN2A
24 cebpa-associated familial acute myeloid leukemia 10.5 PICALM NUP214 MLLT10 FLT3
25 childhood medulloblastoma 10.5 MYC DDX3X CDKN2A
26 chronic leukemia 10.5 FLT3 BCR ABL1
27 plasmablastic lymphoma 10.5 MYC CDKN2A
28 ovary adenocarcinoma 10.5 MYC CDKN2A BAX
29 b-cell adult acute lymphocytic leukemia 10.5 BCR ABL1
30 thyroid lymphoma 10.5 PICALM CDKN2A
31 b-lymphoblastic leukemia/lymphoma with iamp21 10.5 TLX3 ABL1
32 sezary's disease 10.4 TRB MYC BCL10
33 gastrointestinal stromal tumor 10.4 FLT3 CDKN2A BCR ABL1
34 hematologic cancer 10.4 PICALM MYC MLLT10 FLT3 BCR ABL1
35 bone marrow cancer 10.3 MYC FLT3 ABL1
36 ovarian serous cystadenocarcinoma 10.3 MYC CDKN2A BAX
37 leukemia, t-cell, chronic 10.2
38 li-fraumeni syndrome 10.2 MYC CDKN2A BAX
39 alk-negative anaplastic large cell lymphoma 10.1 MYC BAX
40 retinal detachment 10.1
41 thymoma, familial 10.1
42 sickle cell anemia 10.1
43 disseminated intravascular coagulation 10.1
44 pancytopenia 10.1
45 myeloproliferative neoplasm 10.1
46 acute pancreatitis 10.1
47 antiphospholipid syndrome 10.1
48 thymoma 10.1
49 pancreatitis 10.1
50 adult acute lymphocytic leukemia 10.1

Graphical network of the top 20 diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia:



Diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for Precursor T-Cell Acute Lymphoblastic Leukemia

MGI Mouse Phenotypes related to Precursor T-Cell Acute Lymphoblastic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 ABL1 BAX BCL10 BCR CDKN2A CNOT3
2 embryo MP:0005380 10.18 ABL1 BCL10 CDKN2A CNOT3 DDX3X MYB
3 growth/size/body region MP:0005378 10.15 ABL1 BAX BCR CDKN2A CNOT3 DDX3X
4 hematopoietic system MP:0005397 10.1 ABL1 BAX BCL10 BCR CDKN2A CNOT3
5 immune system MP:0005387 10.07 ABL1 BAX BCL10 BCR CDKN2A CNOT3
6 mortality/aging MP:0010768 9.83 ABL1 BAX BCL10 BCR CDKN2A CNOT3
7 liver/biliary system MP:0005370 9.7 ABL1 BCR CDKN2A CNOT3 MYB MYC
8 nervous system MP:0003631 9.36 ABL1 BAX BCL10 BCR CDKN2A DDX3X

Drugs & Therapeutics for Precursor T-Cell Acute Lymphoblastic Leukemia

Drugs for Precursor T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
2
Dasatinib Approved, Investigational Phase 2, Phase 3 302962-49-8 3062316
3
Vorinostat Approved, Investigational Phase 2, Phase 3 149647-78-9 5311
4
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
5
Azathioprine Approved Phase 3 446-86-6 2265
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Blinatumomab Approved, Investigational Phase 3 853426-35-4
8
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
9
leucovorin Approved Phase 3 58-05-9 6006 143
10
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
14
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
15
Pegaspargase Approved, Investigational Phase 3 130167-69-0
16
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
17
Mercaptopurine Approved Phase 3 50-44-2 667490
18
Ichthammol Approved Phase 3 8029-68-3
19
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
20
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
23
Daunorubicin Approved Phase 3 20830-81-3 30323
24
Thioguanine Approved Phase 3 154-42-7 2723601
25
Ifosfamide Approved Phase 3 3778-73-2 3690
26
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
27
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
28
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
30
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
31 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
32
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
33
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
36
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
37
Cortisone Experimental Phase 3 53-06-5 222786
38
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
39 Interferon alpha-2 Phase 3
40 interferons Phase 3
41 Interferon-alpha Phase 3
42 Protein Kinase Inhibitors Phase 3
43 Imatinib Mesylate Phase 3 220127-57-1 123596
44 Histone Deacetylase Inhibitors Phase 2, Phase 3
45 Cardiotonic Agents Phase 3
46 razoxane Phase 3
47 Antibodies, Bispecific Phase 3
48 Proteasome Inhibitors Phase 3
49
protease inhibitors Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
2 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
3 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
4 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
5 Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
6 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
7 International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Recruiting NCT03643276 Phase 3 Blinatumomab;Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;DAUNOrubicin Liposomal Injection [DaunoXome];Dexamethasone;Doxorubicin;Etoposide;Fludarabine Phosphate;Ifosfamide;6-Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Tioguanin;Vincristine;Vindesine;Erwinase
8 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine;Thioguanine
9 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
10 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
11 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
12 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
13 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
14 Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7) Completed NCT00684619 Phase 2 Nelarabine
15 A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
16 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
17 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
18 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
19 An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer Completed NCT00901342 Phase 2
20 Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease. Completed NCT00358072 Phase 2
21 A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
22 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
23 Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine Sulfate
24 A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia Recruiting NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
25 A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell ALL, and Mixed Phenotype Acute Leukemia Recruiting NCT04128501 Phase 2 Azacitidine;Venetoclax
26 An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
27 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
28 International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia Recruiting NCT03705507 Phase 1, Phase 2 Selumetinib;Dexamethasone
29 Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children Recruiting NCT04340154 Phase 2
30 Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study Recruiting NCT04224571 Phase 2 Bortezomib Injection;rituximab injection
31 Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children Recruiting NCT02339350 Phase 2 high dose methotrexate;Intrathecal triple chemotherapy
32 A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT02484430 Phase 2 Sapanisertib
33 Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
34 A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Not yet recruiting NCT04315324 Phase 2 AKR1C3-activated Prodrug OBI-3424
35 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Not yet recruiting NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
36 Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
37 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
38 A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens. Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
39 A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Terminated NCT00742495 Phase 1, Phase 2 Forodesine
40 A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Terminated NCT02767934 Phase 2
41 A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated NCT01483690 Phase 1, Phase 2 Decitabine;Vorinostat;Vincristine;Dexamethasone;Mitoxantrone;Pegaspargase;Methotrexate
42 A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
43 A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer Terminated NCT01420965 Phase 2 CT-011 (Anti-PD1 Antibody);Cyclophosphamide
44 A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma Withdrawn NCT02538926 Phase 2 Asparaginase;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Imatinib Mesylate;Prednisone;Vincristine Sulfate
45 Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT01363817 Phase 1 BMS-906024;Dexamethasone
46 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00608361 Phase 1 Dasatinib
47 Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies Completed NCT01567709 Phase 1 Alisertib;Vorinostat
48 Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors Completed NCT00640796 Phase 1 Chemotherapy
49 A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma Completed NCT01403415 Phase 1 Dexamethasone;Methotrexate;Mitoxantrone Hydrochloride;Pegaspargase;Temsirolimus;Vincristine Sulfate
50 Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. Completed NCT00406757 Phase 1 Nelarabine injection 400mg/m2;Nelarabine injection 650mg/m2;Nelarabine injection 1000mg/m2;Nelarabine injection 1500mg/m2

Search NIH Clinical Center for Precursor T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for Precursor T-Cell Acute Lymphoblastic Leukemia

Anatomical Context for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards organs/tissues related to Precursor T-Cell Acute Lymphoblastic Leukemia:

40
T Cells, B Cells, Myeloid, Bone, Bone Marrow, Testes, Prostate

Publications for Precursor T-Cell Acute Lymphoblastic Leukemia

Articles related to Precursor T-Cell Acute Lymphoblastic Leukemia:

(show top 50) (show all 3741)
# Title Authors PMID Year
1
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. 54 61
20516195 2010
2
Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. 54 61
20459861 2010
3
Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. 61 54
20155852 2010
4
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. 61 54
20124220 2010
5
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. 54 61
20015880 2010
6
T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. 54 61
19631984 2010
7
Genetic inactivation of Ikaros is a rare event in human T-ALL. 61 54
19796813 2010
8
Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. 61 54
19608273 2010
9
Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia. 61 54
20374994 2010
10
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 61 54
19559479 2010
11
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 54 61
20008304 2010
12
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 61 54
20093438 2010
13
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 54 61
20161710 2010
14
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 54 61
20023257 2010
15
Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. 54 61
20208138 2010
16
NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells. 54 61
19835636 2009
17
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. 54 61
19635999 2009
18
Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. 54 61
19564891 2009
19
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. 54 61
19357700 2009
20
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. 54 61
19340001 2009
21
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. 54 61
19458356 2009
22
WT1 mutations in T-ALL. 54 61
19494353 2009
23
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. 54 61
19246562 2009
24
Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors. 61 54
19171877 2009
25
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. 61 54
19469710 2009
26
The mechanism of chemokine receptor 9 internalization triggered by interleukin 2 and interleukin 4. 54 61
19567201 2009
27
Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. 61 54
19091404 2009
28
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. 61 54
19109228 2009
29
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 61 54
19245433 2009
30
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. 54 61
19318552 2009
31
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. 54 61
19351820 2009
32
[Functional analysis of notch in the pathophysiology of leukemia]. 61 54
19489437 2009
33
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. 61 54
19185842 2009
34
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. 61 54
19001083 2009
35
The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus. 61 54
19055661 2009
36
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. 61 54
19778842 2009
37
The role of NOTCH1 signaling in T-ALL. 61 54
20008221 2009
38
CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. 61 54
18683236 2008
39
Notch1 is a frequent mutational target in chemically induced lymphoma in mouse. 54 61
18798262 2008
40
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. 61 54
18830414 2008
41
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. 54 61
18835836 2008
42
Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. 61 54
18981238 2008
43
Relative expression of different Ikaros isoforms in childhood acute leukemia. 54 61
18675565 2008
44
[Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols]. 61 54
19176062 2008
45
[Comparative analysis of blast immunophenotype between the diagnosis and relapse of childhood acute lymphoblastic leukaemia - implications for monitoring of minimal residual disease]. 61 54
19531824 2008
46
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. 54 61
18577685 2008
47
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. 54 61
18677410 2008
48
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. 61 54
18765521 2008
49
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. 61 54
18411416 2008
50
Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution. 54 61
18617057 2008

Variations for Precursor T-Cell Acute Lymphoblastic Leukemia

ClinVar genetic disease variations for Precursor T-Cell Acute Lymphoblastic Leukemia:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABL1 Translocation Pathogenic 617566 9:133709770-133709771
2 BCL10 NM_003921.5(BCL10):c.136dup (p.Ile46fs)duplication Pathogenic 6259 rs387906351 1:85736510-85736511 1:85270827-85270828
3 BAX NM_138761.4(BAX):c.199G>A (p.Gly67Arg)SNV Pathogenic 9513 rs398122513 19:49459056-49459056 19:48955799-48955799
4 BAX NM_138761.4(BAX):c.115_121del (p.Gly39fs)deletion Pathogenic 9514 rs398122840 19:49458971-49458977 19:48955714-48955720

Expression for Precursor T-Cell Acute Lymphoblastic Leukemia

Search GEO for disease gene expression data for Precursor T-Cell Acute Lymphoblastic Leukemia.

Pathways for Precursor T-Cell Acute Lymphoblastic Leukemia

GO Terms for Precursor T-Cell Acute Lymphoblastic Leukemia

Cellular components related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 STIL PICALM NUP214 MYB MLLT10 FLT3
2 nucleus GO:0005634 9.83 TLX3 TLX1 TAL1 PICALM NUP214 MYC
3 protein-containing complex GO:0032991 9.17 TAL1 MYC MLLT10 FLT3 BCR BCL10

Biological processes related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.84 FLT3 BCL10 BAX ABL1
2 positive regulation of transcription, DNA-templated GO:0045893 9.73 TAL1 PICALM MYC MYB CDKN2A BCL10
3 positive regulation of apoptotic process GO:0043065 9.72 DDX3X CDKN2A BCL10 BAX ABL1
4 neural tube closure GO:0001843 9.69 STIL BCL10 ABL1
5 hemopoiesis GO:0030097 9.67 TAL1 PICALM FLT3
6 regulation of hematopoietic stem cell differentiation GO:1902036 9.63 TAL1 MYB ABL1
7 definitive hemopoiesis GO:0060216 9.56 TAL1 BCR
8 regulation of stem cell population maintenance GO:2000036 9.55 TAL1 CNOT3
9 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.54 MYC DDX3X BCL10
10 hypothalamus development GO:0021854 9.52 MYC BAX
11 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.48 CDKN2A ABL1
12 regulation of cell cycle GO:0051726 9.46 NUP214 BCR BAX ABL1
13 B cell apoptotic process GO:0001783 9.43 BCL10 BAX
14 leukocyte homeostasis GO:0001776 9.4 FLT3 BAX
15 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 TLX3 TLX1 TAL1 MYC MYB MLLT10
16 positive regulation of neuron death GO:1901216 9.13 PICALM MYB ABL1

Molecular functions related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.43 TLX3 TLX1 TAL1 MYC MYB MLLT10
2 DNA binding GO:0003677 9.28 TLX3 TLX1 TAL1 MYC MYB MLLT10

Sources for Precursor T-Cell Acute Lymphoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....